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Abstract
Objective: Several studies showed that amoxicillin plus clavulanic acid (co-amoxiclav) is one of the most
common agents associated to serious Drug Induced Liver Injury (DILI). We estimated the risk of acute serious DILI
associated with amoxicillin alone compared with co-amoxiclav, through a multicenter case-control study carried out
in nine Italian hospitals from October 2010 to January 2014.
Methods: Cases were adults, with a diagnosis of acute liver injury. Controls presented acute clinical disorders,
not related to chronic conditions and not involving the liver. Adjusted Odds Ratio (ORs) with 95% CI were calculated
initially with a bivariate and then multivariate analysis.
Results: We analysed 179 cases matched to 1770 controls. Seven cases were exposed to amoxicillin (adjusted
OR 1.69, 95% CI 0.72-3.98) and 22 cases to co-amoxiclav (adjusted OR 3.00, 95% CI 1.76-5.40).
Conclusions: Co-amoxiclav almost doubled the risk of serious acute liver injury compared to amoxicillin alone.
The incidence of co-amoxiclav induced DILI is very low but the widespread use of this drug by the general
population makes the risk clinically relevant. The often inappropriate prescription of antimicrobial agents, and in
particular of co-amoxiclav, could expose a given patient to a life-threatening risk compared to a negligible clinical
benefit.
Keywords: Adverse drug reaction; Case-control study;
Pharmacovigilance; Pharmacoepidemiology Beta-lactams; Antibiotics;
Liver damage
Introduction
Beta-lactams are the most commonly prescribed antibacterial
agents, with large variability across geographical areas [1]. Amoxicillin
is used to treat infections caused by susceptible bacteria, such as
Escherichia coli, Haemophilus influenzae, Staphylococcus aureus
(non-penicillinase producing) and Streptococcus pneumoniae; its
combination with clavulanic acid (co-amoxiclav), a potent inhibitor of
many bacterial beta-lactamase enzymes, broadens its antimicrobial
spectrum. These drugs have been widely used in the outpatient setting
for the treatment of community-acquired respiratory tract and other
mild-to-moderate infections and in recent years an increased
consumption of co-amoxiclav compared to amoxicillin alone has been
observed [1].
Several studies showed that co-amoxiclav is one of the most
common agents associated to severe drug induced liver injury (DILI)
[2-4] and multiple case reports of co-amoxiclav hepatotoxicity have
been published since its first marketing [5,6]. In both Latin American
and Spanish registries of DILI co-amoxiclav ranks first among drugs
involved in liver damage [7]. The liver injuy is reported often as
secondary to hypersensitivity drug allergy resulting in centrizonal
cholestasis, progressing to hepatocellular damage. In severe reactions,
bile duct injury has been reported. The liver injury was mainly related
to the clavulanic acid component; as a matter of fact, there are only few
reports of hepatic reactions with amoxicillin alone [8-10].
Furthermore, the role of clavulanic acid at the onset of liver damage is
supported by data on positive rechallenge (second episode of hepatitis)
only after re-administration of co-amoxiclav and not after amoxicillin
alone [11]. However, a limited number of studies are available in
scientific literature in which a direct comparison between amoxicillin
and co-amoxiclav was made. Rodríguez et al. [12], conducted a
retrospective cohort study in the United Kingdom in order to estimate
the risk of acute liver injury associated with the combination of
amoxicillin and clavulanic acid and to compare it with the risk related
to amoxicillin alone. Salvo et al. [13] analyzed the Italian database of
spontaneous reporting of suspected adverse drug reactions (ADRs) in
order to compare the safety profile of these two drugs. Even though
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applying different methodologies, both studies found that co-
amoxiclav is more hepatotoxic than amoxicillin alone.
Here we present the results of the Drug-Induced Liver Injury case-
control study in Italy (DILI-IT) [14] concerning the pre-specified
subgroup analysis on the risk of acute serious liver injury associated to
amoxicillin and co-amoxiclav.
Methods
The DILI-IT study recruited cases and controls among nine
hospitals located in four Italian regions, from October 2010 to January
2014. A detailed description of the methods has already been
published elsewhere [14].
We used the following criteria for case definition: all patients aged
18 or over, admitted with a primary diagnosis of acute liver injury
according to an increase of 2N (N is the upper limit of normal range
and each activity is expressed as a multiple of N) for alanine
aminotransferase (ALT), aspartate aminotransferase (AST) serum
activity in patients who presented symptoms or not and/or an increase
of 1.5 N of alkaline phosphatase associated with an increase of ALT or
AST and/or total bilirubin in patients with or without symptoms
[15,16].
Controls were patients with a minimum age of 18 years, admitted
for acute clinical disorders not related to chronic conditions, not
involving the liver (with normal liver profile values). Ten hospital
controls were selected consecutively for each case, matched according
to gender and age (+/- 5 years), and to hospital and time from
admission (within 2 months). Both cases and controls were excluded if
the patients had a diagnosis of viral hepatitis, biliary abnormality,
history of alcohol abuse, autoimmune disease, genetic and metabolic
disorders which may determine liver injury, a low alpha-1-antitrypsin
level and an abnormal phenotype (that may suggest disease associated
with a deficiency of this protein), Wilson’s disease, HIV/AIDS, hepatic
neoplasia or liver metastasis, mushroom poisoning and drug addiction
or detoxification treatment in the last 3 months. According to primary
exclusion criteria, patients who were not resident in the study areas
were also excluded. Finally, patients who were discharged or died
before interview and those refused the interview or were unable to
answer were also excluded (secondary exclusion criteria).
Exposure to drugs was defined as any use in the 90 days prior to the
index day (onset day of the liver damage symptoms or the date
corresponding to the first available abnormal value of liver enzyme
tests) [16] and was investigated in a face to face interview using a
standardized questionnaire. Data concerning the diagnosis of liver
injury and the evolution of the disease were collected from medical
records. Clinical records were also used to evaluate the diagnoses of the
controls.
Statistical analysis of data provided for the calculation of Odds
Ratios (OR) and their 95% confidence intervals (95% CI), by means of
a conditional logistic regression for matched case-control groups, were
made using the Stata Statistical Software version 11.0 (StataCorp
2009). In order to assure that the risk estimates for liver injury and use
of drugs were appropriately adjusted for possible confounders and
effect modifiers, OR has been computed initially with a bivariate and
then multivariate analysis. Covariates included were: smoking, alcohol,
body mass index (BMI), liver comorbidities (hepatitis, gallstones, liver
cirrhosis, hepatic nodules and other hepatic diseases), heart
comorbidities (stroke, angina pectoris, heart failure, arrhythmia and
cardiac surgery), and concomitant drugs (NSAIDs, paracetamol,
macrolides, antidepressants and statins).
The study was approved by the Independent Ethics Committee
(IEC) of Verona Hospital (principal investigator and coordinating
centre) and consecutively notified to the IECs of participating centres.
Results
Overall, 2232 patients with diagnosis of acute serious liver injury
were recorded in DILI-IT Study; of those, 2028 were not included in
the study, according to the primary exclusion criteria. Subsequently,
other 25 cases were excluded on the basis of secondary criteria.
Therefore, the analysis was performed on 179 cases. In the same
period, 3059 patients were selected and interviewed as possible
controls. A study flow chart is available in the DILI-IT Study
manuscript [14]. From this sample, 1770 patients were matched to the
179 cases, according to gender, age, centre, and time of admission.
Controls included in the analysis were enrolled for the following
diagnosis: trauma or fracture (46%), acute appendicitis (15%),
gastrointestinal disorders (14%), respiratory disorders (13%), other
acute events (12%). Except for drugs consumption (cases used more
drugs than controls), there were no significant differences between
cases and controls relating to BMI, school level, alcohol consumption
and tobacco use, cardiovascular and hepatic concomitant disease.
During the three months before the index day, 7 cases (4% of 179)
were exposed to amoxicillin and 22 (12%) to co-amoxiclav, resulting in
an annual incidence of 0.1 and 0.4 cases per 100,000 inhabitants,
respectively. In the same period, 37 controls (2% of the 1770) were
exposed to amoxicillin and 63 (4%) to co-amoxiclav. Table 1 shows the
baseline characteristics of these patients. Also these subgroups of
patients did not reveal any significant differences between cases and
controls, except for drug consumption.
 Amoxicillin Co-amoxiclav
Characteristic Cases n=7 Controls n=37 P value Cases n=22 Controls n=63 P value
Sex, n (%)   0.09   0.14
Male 0 (0) 13 (35)  13 (59) 27 (43)  
Female 7 (100) 24 (65)  9 (41) 36 (57)  
Age (years), mean ± sd 42 ± 25.8 45.6 ±18.9 0.67 44.7 ± 17.8 42.8 ± 16.4 0.65
Schooling level (years), mean ± sd 12.1 ± 6.2 11.6 ± 4.5 0.8 11.1 ± 4.7* 10.4 ± 4.3* 0.52
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BMI, mean ± sd 24.1 ± 6.8 24.6 ± 3.6 0.77 24.6 ± 3.6 24.7 ± 4.0 0.92
Alcohol, n (%)   0.99   0.51
Current drinker 4 (57) 19 (51)  16 (73) 39 (62)**  
Former drinker 0 (0) 1 (3)  1 (4) 2 (3)  
Non-drinker 3 (43) 17 (46)  5 (23) 21 (33)  
Smoke, n (%)   0.17   0.99
Current smoker 3 (43) 5 (14)  7 (32) 21 (33)  
Former smoker 1 (34) 6 (16)  3 (14) 8 (13)  
Non-smoker 3 (43) 26 (70)  12 (54) 34 (54)  
Co-morbidities, n (%)       
Liver diseases 0 (0) 4 (11) 0.99 3 (14) 7 (11) 0.71
Heart diseases 2 (29) 4 (11) 0.99 2 (9) 5 (8) 0.99
Number of drugs, mean ± sd 6.9 ± 3.3 3.6 ± 1.6 <0.001 4.9 ± 2.7 3.6 ± 2.4 0.04
*result from 21 cases and 61 controls (96.5% of data) **result from 62 controls (98.4% of data)
Table 1: Baseline characteristics of patients in study population.
About 60% of cases taking co-amoxiclav were men, while 100% of
cases exposed to amoxicillin were women; average age, school level
and BMI in the two groups were approximately the same. Concomitant
cardiovascular diseases were more frequent in cases taking amoxicillin
(29%), than in cases taking co-amoxiclav (9%); on the contrary,
concomitant liver diseases were present only in the latter (3 cases of
light steatosis). Cases treated with amoxicillin alone used more drugs
than the co-amoxiclav group (6.9 ± 3.3 and 4.9 ± 2.7 respectively),
however the percentages of patients with concomitant known
hepatotoxic drugs were similar.
Table 2 shows the OR estimates of acute serious liver injury
associated with amoxicillin and co-amoxiclav: only the association
with clavulanic acid was associated to a statistically significant
increased risk of liver damage, with an adjusted OR equal to 3.00 (95%
CI, 1.76-5.40). The nature of liver enzyme abnormality was mainly










Amoxicillin 7 (4%) 37 (2%) 1.94 (0.85-4.44) 1.69 (0.72-3.98)
Co-
amoxiclav 22 (12%) 63 (4%) 3.08 (2.42-7.05) 3.00 (1.76-5.40)
Table 2: Risk of acute serious drug-induced liver injury associated with
amoxicillin and amoxicillin/clavulanic acid.
Discussion
Our data show that the combination of amoxicillin with clavulanic
acid is significantly associated with a risk of DILI almost double
compared to amoxicillin alone. The corresponding incidences are very
low (0.1 cases for amoxicillin alone and 0.4 cases for amoxicillin
+clavulanic acid for 100.000 inhabitants year, respectively), in line with
other estimates from published data [5,15,17,18]. However, the true
incidence of DILI is difficult to compute for several reasons; the most
relevant ones are the following: the denominator of individuals
receiving a drug is unknown, a simple objective test for the diagnosis
of DILI is still lacking, and the causality of attribution to a single drug
in patients exposed to many drugs is hard to determine [19].
The risk of co-amoxiclav induced DILI is known to be linked to
clavulanic acid, since its association with other beta-lactam antibiotics
has shown some hepatotoxicity [20,21].
The amoxicillin component of the drug is primarily excreted by
renal system, whereas clavulanic acid is excreted by both the kidney
and liver. The mechanism of co-amoxiclav induced hepatitis is not
completely clarified, but the frequent association with hypersensitivity
reactions (i.e. skin rash, hypereosinophilia, anti-tissue antibodies)
suggests an immune-allergic mechanism [22,23]. The reaction could be
due also to an idiosyncratic response to the drug [12]. Moreover,
currently available evidence suggests a genetic susceptibility to co-
amoxiclav induced liver injury in patients with specific HLA haplotype
[24,25].
Our findings, even though resulting from a small sample of
observations, show a gender difference in risk of DILI associated with
amoxicillin and co-amoxiclav. The observed higher risk for co-
amoxiclav in men is consistent with published data, such as those of
Gresser [26] showing that 106 out of 153 cases of hepatitis were men.
Concomitant multi drug therapy is an acknowledged risk factor for
DILI, and our findings show that cases associated with both
amoxicillin or co-amoxiclav were exposed to a higher number of drugs
than controls. According to Yazici et al. [27], the risk of death among
users of co-amoxiclav increases with the use of concomitant
hepatotoxic medications and they suggest that these patients may have
concomitant diseases with less ability to recover from a severe DILI
compared to healthier patients, or even that the occurrence of drug-
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drug interactions between amoxiclav and other hepatotoxic agents may
result in a more serious liver injury. In their recent paper Suzuki et al.
[28] analyzed the reporting frequency of liver events of four drugs (one
of them was co-amoxiclav) in the presence of co-reported medications
on the basis of the WHO global individual case safety report database
(VigiBase™); they showed that co-reported drugs were associated with
changes in the frequency of hepatic ADR reporting of drugs usually
associated with hepatotoxicity, suggesting that co-medications could
modify drug hepatic safety.
Our findings are also consistent with a published pharmacovigilance
analysis from the Italian spontaneous reporting system database by
Salvo et al. [13], which highlighted that co-amoxiclav use was
associated with a higher frequency of liver injuries compared with
amoxicillin alone.
Although the absolute risk of co-amoxiclav-induced DILI is
generally very low, as in the case of the present work, it must be also
interpreted in relation to the widespread use of the drug, which
continuously increased over the years. In Italy, co-amoxiclav is the
most prescribed antimicrobial agent (41% of total antibiotics use) and
among the most prescribed drugs [29], both for adults and pediatric
patients. In the period 2007-2015 co-amoxiclav use increased from 7.3
to 9.4 DDD/1000 inhabitants/day, whereas amoxicillin use decreased
from 3.9 to 2.1.
These evidence raise concern regarding the inappropriate
prescribing of co-amoxiclav in particular for respiratory tract
infections, for which several international guidelines still
recommended amoxicillin as first line antibiotic treatment [30].
According to Butler et al. [31], antibiotic prescriptions virtually never
benefit patients with acute cough, which is instead one of the most
common reasons for antibiotic prescribing in the community. In Italy
the prevalence of inappropriate use of antibiotics in upper respiratory
tract infections has been estimated as 37.1% [29]. Another aspect
suggesting a certain degree of inappropriateness in the use of
penicillins for infections of the respiratory tract is represented by the
seasonal variation in the use of such drugs. In fact, the Italian Report
on the use of antibiotic drugs in 2009 [32] showed a correlation
between the monthly incidence of influenza cases and antibiotic
consumption. The treatment of disorders of viral origin with
antibiotics is not only inappropriate, but can also substantially
contribute to the development of antibiotic resistance.
The limitations and advantages of the main study have already been
declared [14]. Among the others, the retrospective nature of the survey
(case-control design), with the consequent difficulties to establish the
temporal relationship between exposure and disease, as well as the
difficulty of patients surveyed recall events that occurred long time
before. Moreover, in this manuscript we reported the results of a
subgroup of patients exposed to amoxicillin and co-amoxiclav, with all
the limitations of the subgroup analysis [33,34], but it should be noted
that this analysis was a pre-specified secondary endpoint in the study
protocol. Among the strengths we find the methods for measuring
consumption and possible damage due to amoxicillin and co-
amoxiclav, performed by direct administration of questionnaires to
patients, who provided information collected and validated by each
clinical monitor involved in the study. In addition, the data obtained
are representative of the whole Italian population, having involved
patients of Northern, Central and Southern Italy.
In conclusion, compared to amoxicillin alone, amoxicillin
+clavulanic acid doubles the risk of serious acute liver injury, in
agreement with most studies on DILI [15]. The incidence of co-
amoxiclav induced DILI is very low, however given the widespread use
of this drug in the general population, the risk should be considered
clinically relevant. The very often inappropriate prescription of
antimicrobial agents, and in particular of co-amoxiclav, could expose a
given patient to a life-threatening risk compared to a negligible clinical
benefit.
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